Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$AURX 7 filings in ONE DAY?? I wonder why do many insiders bought at the same time??
And bought at an exercise price of .22?
Add in the share structure....... shares are SCARCE!
$AURX big time player in a huge multi billion dollar industry
A MUST READ
https://www.marketwatch.com/press-release/platelet-rich-plasma-market-forecast-to-touch-us-45-billion-by-2024-2019-01-04
Charles E. Sheedy, CFA
Senior Vice President
Portfolio Management
Investment Committee Member
Charles E. Sheedy is a Senior Vice President at Fayez Sarofim & Co. and a member of the Firm’s Investment Committee. He is co-manager of the mutual funds that Fayez Sarofim & Co. manages for The Dreyfus Corporation and serves on the board of Sarofim Trust Co. Additionally, he is a portfolio manager for a variety of institutional and high net worth clients. Mr. Sheedy joined the Firm 1971 as an Associate. Over the years, areas of responsibility have included retail, electrical equipment, consumer staples, basic industries and health care.
Mr. Sheedy received a M.B.A. from Harvard Business School in 1971 and graduated cum laude from the University of Notre Dame in 1969.
Mr. Sheedy is a member of the Notre Dame Arts & Letters Advisory Counsel.
https://www.sarofim.com/leadership.html
AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX
$AURX .09 FLOAT 1.8M (not a misprint). WOW.
$AURX INSIDER bought 5.2 million shares at 22 cents!! That's well over a million bucks folks. AND YOU IGNORE 9 CENTS???!! 6 INSIDERS LOADED 2 days ago!! Something brewing
http://insideri.com/1005483_000089924317020218_0000899243-17-020218
AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX
Charles E. Sheedy, CFA
Senior Vice President
Portfolio Management
Investment Committee Member
Charles E. Sheedy is a Senior Vice President at Fayez Sarofim & Co. and a member of the Firm’s Investment Committee. He is co-manager of the mutual funds that Fayez Sarofim & Co. manages for The Dreyfus Corporation and serves on the board of Sarofim Trust Co. Additionally, he is a portfolio manager for a variety of institutional and high net worth clients. Mr. Sheedy joined the Firm 1971 as an Associate. Over the years, areas of responsibility have included retail, electrical equipment, consumer staples, basic industries and health care.
Mr. Sheedy received a M.B.A. from Harvard Business School in 1971 and graduated cum laude from the University of Notre Dame in 1969.
Mr. Sheedy is a member of the Notre Dame Arts & Letters Advisory Counsel.
https://www.sarofim.com/leadership.html
AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX
AURX
//www.nuot.com/
http://aurixsystem.com/for-patients/ ;
https://vimeo.com/131799809 ;
AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX
$AURX INSIDER bought 3.5 MILLION shares! http://insideri.com/1683332_000168316817002435_0001683168-17-002435
AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX
$AURX INSIDER bought 5.2 million shares!! http://insideri.com/1005483_000089924317020218_0000899243-17-020218
$AURX 0885 WHY DO INSIDERS OWN OVER 72% OF SHARES? UNKNOWN to 99.99999% of traders, moves on a air on a power scale less than a whisper #BIOTECH GEM. 6 INSIDERS just ADDED SHARES YESTERDAY and I'm the only trader that knows (I guess)!!!!? Form 4 filing silently out today, NO ONE NOTICED. WHY?????? Last time I alerted it at .05 it ran to .575 in 5 days. Nothing has changed since then...oh wait 1 thing has ch as aged, INSIDERS BOUGHT MORE SHARESSSSSS!
David Jorden: Peter Clausen:
Eric Winzer: Scott Pittman: Lawrence Atinsky: Paul Mintz: ALL LOADED!! Exercise price ...wait for it... 40 CENTS!!! Shhhhh.
Private placement at 30 cents and traders are ignoring this BOTTOM at 7 cents?! I'm compelled to ask myself do I have super vision or is everyone else using a Navigation system created by the 3 blind mice? What more can i say? I'm trying to keep it do simple a 4 year old could understand it.
The only thing common about common sense is that it's UNCOMMON.
People fail to get in my plays at BOTTOM. I'm in at 7 cents
https://www.otcmarkets.com/stock/AURX/disclosure
AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX
AURX~~600k CASH ,AURX~~As of November 12, 2018, we had cash and cash equivalents of approximately $0.6 million.
AURX~~As of November 12, 2018, we had cash and cash equivalents of approximately $0.6 million.
AURX~~.05/.20 crazy thih on L2
AURX~~INSIDER BUYING CRAZYY
Are you talking about AURX?
Pull certs
Shorty is getting nervous. There is rumored to be a massive short squeeze coming soon. My sources tell me the funding for the payout is tied to Trump's border wall. Stay tuned.
It look like it will go back up..
IMO
Very risky stock with such low volume
Dollars coming
This is not a good stock to enter the volume is way too low the spreads are way too big
Timmmmmberrrrrr
Whale bid was the clue to chuck
Why so much dumping today? Dilution?
Agree.. Boom Time!
IMO
WALL ON BID
SIZE
LARGEST SIZE SHES SEEN
Unbelievable how well this performed yesterday, my 50K freebies looking better by the hour, gonna thin a few today to throw into another stock that's ready to pop off this is going to be a sweet week congrats all.
I think your right we WARCHEST we are headed for a dollar++ !!!!
Global Globoid Cell Leukodystrophy Treatment Market 2018: Novartis, Commence, Kyorin, Nuo Therapeutics
Globoid Cell Leukodystrophy Treatment MarketGlobal Globoid Cell Leukodystrophy Treatment Market Research Report 2018 offers a unique instrument for assessing the market, featuring possibilities, and helping strategic and tactical decision-making. This Globoid Cell Leukodystrophy Treatment Market report perceives that in this quickly advancing and competitive situation, current marketing facts is important to observe execution and make essential decisions for development and benefit. It gives information on patterns and improvements, and targets in business sectors and materials, limits and innovations, and on the changing structure of the Globoid Cell Leukodystrophy Treatment Sales.
For Market chain examination, the report includes upstream raw materials, downstream customer survey, advertising and marketing channels, equipment, market advancement pattern and proposals, which more mainly covers profitable data onto Globoid Cell Leukodystrophy Treatment key applications and use, key regions and use, global key vendors, main raw materials providers and contact information, leading manufacturing equipment distributors and contact information, main suppliers and contact Information, key purchasers and contact information with statistics, and supply network relationship investigation.
Get Sample of this Report Here: qymarkets.biz/global-globoid-cell-leukodystrophy-treatment-market-2018-by-application-type-key-players-region-and-forecast-to-2022/#Request–Sample
The purposes of this analysis are:
1. To characterize, portray, and check the Globoid Cell Leukodystrophy Treatment market based on product type, application, and region.
2. To estimate and inspect the size of the Globoid Cell Leukodystrophy Treatment market (in terms of value) in six key regions, specifically, North and South America, Western Europe, Central & Eastern Europe, the Middle East, Africa and the Asia-Pacific.
3. To estimate and inspect the Globoid Cell Leukodystrophy Treatment markets at country-level in every region.
4. To strategically investigate every sub-market about personal development trends and its contribution to the Globoid Cell Leukodystrophy Treatment market.
5. To look at possibilities in the Globoid Cell Leukodystrophy Treatment market for shareholder by recognizing excessive-growth segments of the market.
Worldwide Globoid Cell Leukodystrophy Treatment Sales (K Units) and Revenue (Million USD) Market by Leading Manufacturers 2018-2025 are; Commence Bio Inc, Kyorin Pharmaceutical Co Ltd, Novartis AG, Nuo Therapeutics Inc.
Based on product manufacturing, market sales, cost, share and growth rate of each type, report primarily split into; RND-001, CMB-200, DUOC-01, Others.
Based on the end users/Application, this report covers status and outlook, consumption (sales), market share, and growth rate of each application, including Hospital, Clinic, Research Center.
Access entire report of this research with TOC and List of Figures at: qymarkets.biz/global-globoid-cell-leukodystrophy-treatment-market-2018-by-application-type-key-players-region-and-forecast-to-2022/#Buying-Inquiry
This autonomous report promises you will stay higher knowledgeable than your opposition. With over 170 tables and figures inspecting the Globoid Cell Leukodystrophy Treatment market, the report offers you a visible, one-stop breakdown of the main products, sub-markets including market leader’s sales forecasts as well as analysis to 2025.
Geographically, Globoid Cell Leukodystrophy Treatment analysis report isolated into the global top regions, with the help of Market Share (%), Growth Rate (%), Market Sales ($) and income from 2014 to 2025 (forecast), covering the United States, Europe, India, Japan, China and South-east Asia.
The report gives a simple assessment of the Globoid Cell Leukodystrophy Treatment industry such as classifications, applications, definitions and business chain structure as well as the improvement policies and designs are explained and also production procedures and price structures.
The investigation carried out using an aspirational mixture of essential and auxiliary information including contributions from the key contributor in the industry. The report consists of an extensive market and seller perspective as well as a SWOT analysis of the key players.
There are 15 chapters to completely show the worldwide Globoid Cell Leukodystrophy Treatment market report:
Chapter 1, to define Globoid Cell Leukodystrophy Treatment presentation, product outlook, market review, market opportunities, market risk, market driving forces;
Chapter 2, to investigate the leading manufacturers of Globoid Cell Leukodystrophy Treatment, with sales, revenue, and cost of Globoid Cell Leukodystrophy Treatment, in 2017 and 2018;
Chapter 3, to show the competing circumstance between major manufacturers, with income, sales and market share in 2017 and 2018;
Chapter 4, to display the global market by key regions, with regional revenue, regional sales and regional market share of Globoid Cell Leukodystrophy Treatment, from 2014 to 2018;
Chapter 5, 6, 7, 8 and 9, to inspect the key regions, with market share, sales and revenue by key countries in these regions;
Chapter 10 and 11, to analyze the global market by type and application, with growth rate, market share and sales of each region, from 2014 to 2018;
Chapter 12, Globoid Cell Leukodystrophy Treatment market outlook and forecast, by regions, type and application, with revenue and sales, from 2018 to 2025;
Chapter 13, 14 and 15, to depict Globoid Cell Leukodystrophy Treatment deals channel, traders, sellers, distributors, research Findings and conclusion, appendix and data source.
Purposes of Buying Global Globoid Cell Leukodystrophy Treatment Market Report:
• This report gives pin-point investigation toward changing competitive dynamics.
• It gives a forward-looking prospect of various components driving or controlling industry development.
• It gives a mechanical development graph over time to appreciate the market growth rate.
• It gives a seven-year forecast estimate based on how the market anticipated growing.
About Us:-
QYMarkets.biz offers significant market research reports to associations, industries or even people with a goal of assisting them to make their decision technique. These reports encompass comprehensive market research analysis especially industry analysis, information on products, countries, market size, market share, patterns and trends, business research details and many more. QYMarkets.biz gives worldwide and regional market intelligence coverage, a 360-degree market view which incorporates detailed segmentation, key patterns, statistical forecasts, competitive landscape and vital proposals.
+1(855)465-4651 | sales@qymarketresearch.com
http://worldherald24.com/2018/02/16/global-globoid-cell-leukodystrophy-treatment-market-2018-novartis-commence-kyorin-nuo-therapeutics/
Global Sandhoff Disease Therapeutics Sales Market Report 2018
Published: February 2018
No. of Pages: 100
In this report, the global Sandhoff Disease Therapeutics market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025.
Geographically, this report split global into several key Regions, with sales (K Pcs), revenue (Million USD), market share and growth rate of Sandhoff Disease Therapeutics for these regions, from 2013 to 2025 (forecast), covering
- United States
- China
- Europe
- Japan
- Southeast Asia
- India
Global Sandhoff Disease Therapeutics market competition by top manufacturers/players, with Sandhoff Disease Therapeutics sales volume, Price (USD/Pcs), revenue (Million USD) and market share for each manufacturer/player; the top players including
- Bioasis Technologies Inc
- Nuo Therapeutics Inc
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
- ALD-601
- CCP-010
- DUOC-01
- MTf-HEXB
- Others
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
- Clinic
- Hospital
- Others
If you have any special requirements, please let us know and we will offer you the report as you want.
Published By: QYResearch Group
Product Code: QYResearch Group142887
Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and well share relevant market report titles for you to explore.
Related Reports:
Global Rosuvastatin Calcium Market Research Report 2018
In this report, the global Rosuvastatin Calcium market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025. Geographically, this report is segmented into seve...
Global and Chinese Scar Treatment Industry, 2018 Market Research Report
The 'Global and Chinese Scar Treatment Industry, 2013-2023 Market Research Report' is a professional and in-depth study on the current state of the global Scar Treatment industry with a focus on the Chinese market. The report provides key statistics ...
Global and Chinese Saffron Extract Industry, 2018 Market Research Report
The 'Global and Chinese Saffron Extract Industry, 2013-2023 Market Research Report' is a professional and in-depth study on the current state of the global Saffron Extract industry with a focus on the Chinese market. The report provides key statistic...
China Bacterial Vaginosis Drug Market Research Report 2018
The global Bacterial Vaginosis Drug market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. China plays an important role in global market, with market ...
China Morphine Sulfate Market Research Report 2018
The global Morphine Sulfate market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. China plays an important role in global market, with market size of ...
China Fosfomycin Trometamol Market Research Report 2018
The global Fosfomycin Trometamol market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. China plays an important role in global market, with market siz...
China Low Molecular Weight Heparin Market Research Report 2018
The global Low Molecular Weight Heparin market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. China plays an important role in global market, with mar...
China Rasagiline Tablet Market Research Report 2018
The global Rasagiline Tablet market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. China plays an important role in global market, with market size of...
China Hair Loss Supplement Market Research Report 2018
The global Hair Loss Supplement market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. China plays an important role in global market, with market size...
China Lupus Therapeutic Market Research Report 2018
The global Lupus Therapeutic market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. China plays an important role in global market, with market size of...
http://www.reportsnreports.com/reports/1351531-global-sandhoff-disease-therapeutics-sales-market-report-2018.html
wrong, their is more that's going on than you know
$AURX .. very strong day .. as expected in my previous post .. trading thin no doubts watching closely tomorrow if can maintain the strong move it made today ..
So thin, explosive
UP .575!
IMO
Breakout coming!! Hitting .555!!!
IMO
IF break .60 and .80.. Bluesky ahead. MACD has climb above the line.. Weeee!!!!!!!!!!!!!!!
IMO
If the volume hit 1 Million.. We would be up by $2.00
IMO
Stinky rich in my Vegas suite
Followers
|
8
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
154
|
Created
|
02/13/18
|
Type
|
Free
|
Moderators |
Nuo Therapeutics, Inc. is a biomedical company that pioneers leading-edge biodynamic therapies within the emerging opportunities of a changing healthcare landscape.
Through bold leadership, better clinical solutions, and products that add true value to a patient’s health, we aim to offer more effective and efficient therapies for healing.
Nuo Therapeutics’ flagship product, Aurix™, is a biodynamic hematogel that uses a patient’s own platelets and plasma as a catalyst for healing. It is the only therapy of its kind that is FDA-cleared for use on ulcers and wounds of all types.
Dr. Clausen joined Nuo Therapeutics in September 2008 and has more than 20 years of experience in the biotechnology industry. Prior to joining Nuo Therapeutics, Dr. Clausen was a founding member and Vice President of Research and Development at Marligen Bioscience, where he developed and commercialized innovative genomic and protein analysis products for the life sciences market. Dr. Clausen was the Manager of New Purification Technologies at Life Technologies and the Invitrogen Corporation. He also has significant experience within the commercial biotechnology industry developing peptide and small molecule therapeutics for application in the areas of inflammatory mediated disease and stem cell transplantation. He completed his post-doctoral training at the Laboratory of Molecular Oncology at the National Cancer Institute where his research efforts focused in the areas of oncology, hematopoiesis, and gene therapy. Dr. Clausen earned his PhD in Biochemistry from Rush University in Chicago and a Bachelor of Science degree in Biochemistry from Beloit College.
David E. Jorden has been Chief Executive Officer and Chief Financial Officer of the Company effective July 1, 2016 after serving as Acting CEO since January 8, 2016 and Acting CFO since May 2015. Mr. Jorden also serves as Acting Secretary of the Company, and has served on the Board of Directors since October 2008 and was Executive Chairman from February 2012 to May 2015. From 2003 to 2008, he was with Morgan Stanley’s Private Wealth Management group where he was responsible for equity portfolio management for high net worth individuals. Prior to Morgan Stanley, Mr. Jorden served as CFO for Genometrix, Inc., a private genomics/life sciences company focused on high-throughput microarray applications. Mr. Jorden was previously a principal with Fayez Sarofim & Co. Mr. Jorden has a MBA from Northwestern University’s Kellogg School and a B.B.A. from University of Texas at Austin. He holds both Certified Financial Analyst and Certified Public Accountant designations. Mr.Jorden serves on the board of Opexa Therapeutics, Inc. (Nasdaq: OPXA) where he has held the position of Acting Chief Financial Officer since August 2012. He is also on the board of a private companies, PLx Pharma, Inc., a specialty pharmaceutical company developing GI safer NSAIDs (nonsteroidal anti-inflammatory drugs). Mr. Jorden brings his experience and expertise in the areas of capital raising, investor relations, financial management and analysis, and business strategy to the Board and the Company.
Board of Directors
David E. Jorden has been Chief Executive Officer and Chief Financial Officer of the Company effective July 1, 2016 after serving as Acting CEO since January 8, 2016 and Acting CFO since May 2015. Mr. Jorden also serves as Acting Secretary of the Company, and has served on the Board of Directors since October 2008 and was Executive Chairman from February 2012 to May 2015. From 2003 to 2008, he was with Morgan Stanley’s Private Wealth Management group where he was responsible for equity portfolio management for high net worth individuals. Prior to Morgan Stanley, Mr. Jorden served as CFO for Genometrix, Inc., a private genomics/life sciences company focused on high-throughput microarray applications. Mr. Jorden was previously a principal with Fayez Sarofim & Co. Mr. Jorden has a MBA from Northwestern University’s Kellogg School and a B.B.A. from University of Texas at Austin. He holds both Certified Financial Analyst and Certified Public Accountant designations. Mr.Jorden serves on the board of Opexa Therapeutics, Inc. (Nasdaq: OPXA) where he has held the position of Acting Chief Financial Officer since August 2012. He is also on the board of a private companies, PLx Pharma, Inc., a specialty pharmaceutical company developing GI safer NSAIDs (nonsteroidal anti-inflammatory drugs). Mr. Jorden brings his experience and expertise in the areas of capital raising, investor relations, financial management and analysis, and business strategy to the Board and the Company.
Paul D. Mintz, MD was elected to the Nuo Therapeutics, Inc. Board of Directors, effective April 7, 2017. Dr. Mintz is currently the Senior Vice President and Chief Medical Officer of Verax Biomedical. Prior to joining Verax Biomedical in early 2016, Dr. Mintz served as Director, Division of Hematology Clinical Review, Office of Blood Research and Review, Center for Biologics Evaluation and Research of the U.S. Food and Drug Administration. Prior to that, for more than 30 years, Dr. Mintz was a member of the faculty of the University of Virginia School of Medicine, where he was a tenured Professor of Pathology and Internal Medicine. He also served as Vice-Chair of Pathology and Chief of the Division of Clinical Pathology, and as Medical Director of the Clinical Laboratories and Transfusion Medicine Services at the University of Virginia Health System. In addition, Dr. Mintz served as Co-Medical Director of Virginia Blood Services. Dr. Mintz is a former President of the American Association of Blood Banks (AABB), served on the AABB’s Board of Directors for nine years, and was a member of and chaired numerous AABB committees. Dr. Mintz is a recipient of the AABB’s John Elliott Memorial Award. He has also served as a member of the Board of Trustees of the National Blood Foundation. Dr. Mintz is the recipient of a Transfusion Medicine Academic Award from the National Heart, Lung and Blood Institute, and was an inaugural inductee into the National Blood Foundation Hall of Fame. He also served as a member of the Medicare Coverage Advisory Committee of the Centers for Medicare and Medicaid Services (CMS). Dr. Mintz is author or co-author of more than 100 articles and editorials spanning clinical practice, blood safety and the evaluation of new transfusion medicine technologies, and has designed and served as principal investigator for numerous clinical trials. He is the sole editor of all three editions of Transfusion Therapy: Clinical Principles and Practice (AABB Press) and has served on several journal editorial boards. Dr. Mintz earned his BA in Philosophy from the University of Rochester and received his MD with honors from the University of Rochester School of Medicine. Dr. Mintz brings considerable knowledge of platelet biology and transfusion medicine, along with senior regulatory and reimbursement experience to Nuo Therapeutics, and will be enormously valuable as the company strives to advance the Aurix System toward broader commercialization in the large and growing chronic wound care market.
C. Eric Winzer has served as Director since January 30, 2009. Mr. Winzer has over 30 years of experience in addressing diverse financial issues including raising capital, financial reporting, investor relations, banking, taxation, mergers and acquisitions, financial planning and analysis, and accounting operations. Mr. Winzer has been the Chief Financial Officer at Immunomic Therapeutics, Inc., a privately-held clinical stage biotechnology company, since May 2015. From June 2009 to April 2015 Mr. Winzer served as the Principal Accounting Officer, Senior Vice President of Finance, and Chief Financial Officer for OpGen Inc. (OPGN), a precision medicine company that went public in May 2015. Before his tenure with OpGen Inc., Mr. Winzer held multiple executive positions at Avalon Pharmaceuticals, Inc. (AVRX), a NASDAQ listed biotechnology company, including serving as its Chief Financial Officer and Executive Vice President, Principal Accounting Officer, and Secretary. Before joining Avalon Pharmaceuticals, Mr. Winzer held numerous senior financial positions over twenty years at Life Technologies Corporation (LIFE) (now part of Thermo Fisher Scientific (TMO)) and its predecessor companies, Invitrogen (IVGN) and Life Technologies, Inc. (LTEK). From 1980 to 1986, Mr. Winzer held various financial positions at Genex Corporation. Mr. Winzer has been an Independent Director at Nuo Therapeutics (f/k/a Cytomedix, Inc.) since January 30, 2009. Mr. Winzer holds a B.A. in Economics and Business Administration from Western Maryland College (now, McDaniel College) and an M.B.A. from Mount Saint Mary's University. Mr. Winzer was chosen to serve as a director of the Company in part because of his executive experience in the life sciences industry and his substantial financial knowledge and expertise.
Lawrence S. Atinsky has served as a director since May 5, 2016. Mr. Atinsky is a Partner at Deerfield Management Company, LP (“Deerfield Management”), a healthcare investment firm focused on advancing healthcare through investment, information and philanthropy. He primarily focuses on the firm’s structured transactions and private equity investments. Prior to joining Deerfield Management, Mr. Atinsky was a partner of Ascent Biomedical Ventures, a healthcare focused private equity firm investing in early-stage biomedical and medical device companies. He has over 18 years of experience investing in healthcare companies and currently serves on the Board of FluoroPharma Medical, Inc. Mr. Atinsky earned a J.D. from New York University School of Law and B.A. degrees in Political Science and Philosophy from the University of Wisconsin-Madison, cum laude. Deerfield Management’s affiliates are currently the sole holders of our Series A Preferred Stock and Mr. Atinsky serves as their designee to our Board of Directors under the Certificate of Designations for our Series A Preferred Stock.
Scott M. Pittman has served as a director since May 5, 2016. Mr. Pittman has over 30 years in Hospital Executive management. He is a Chief Operating & Business Development Officer for Buchanan General Hospital, a Registered Representative with Calton & Associates, and a Principal of Hospital CEO Associates. He has served as CEO Florida Hospital Zephyrhills, FL, in senior executive positions with Adventist Health Systems, and in various hospital executive positions in southern West Virginia. Mr. Pittman has developed several multimillion dollar hospital and program service expansions, and healthcare entity acquisitions and mergers, and has served on numerous state and regional health planning organizations. He is a Magna cum Laude graduate of Southwestern Adventist University with B.S. & B.A. Degrees in Business and Religion, and a Masters of Hospital Administration from Medical College of Virginia. Mr. Pittman was chosen to serve as a director of the Company in part because of his extensive experience as a hospital executive.
Aurix™ is a biodynamic hematogel that harnesses a patient’s innate healing mechanisms to jumpstart the natural healing process.
Aurix is the first platelet and plasma therapy system to be cleared by the FDA for the management of ulcers and wounds of all types (DFU, pressure, VLU, etc.) and all severities (partial thickness, full thickness, and complex wounds).
Aurix is effective at all stages of wound care for non-healing wounds, allowing providers more treatment flexibility across a broader range of patients.
Aurix™ is a biodynamic hematogel that harnesses a patient’s innate healing mechanisms to jumpstart the natural healing process.
Aurix is the first platelet and plasma therapy system to be cleared by the FDA for the management of ulcers and wounds of all types (DFU, pressure, VLU, etc.) and all severities (partial thickness, full thickness, and complex wounds).
Aurix is effective at all stages of wound care for non-healing wounds, allowing providers more treatment flexibility across a broader range of patients.
For more information about our company or our products, please contact or fill out the form on www.nuot.com/contact/
Corporate Offices
207A Perry Parkway, Suite 1
Gaithersburg, MD 20877
Nashville Office
618 Church St., Suite 305
Nashville, TN 37219
Phone
1.866.298.6633
Fax
1.240.499.2690
Email
info@nuot.com
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |